Analysis of cIAP-1 and cIAP-2 protein expression in cirrhotic stage PSC patients revealed a significantly reduced cIAP-1 and cIAP-2 immunoreactivity in both small and large interlobular bile ducts compared to normal livers or disease control nonalcoholic steatohepatitis (NASH) livers (Figures 1a and b). The gene discussed is BIRC3; the disease is metabolic dysfunction-associated steatohepatitis.